Compare HKIT & PASG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | HKIT | PASG |
|---|---|---|
| Founded | 1996 | 2017 |
| Country | China | United States |
| Employees | N/A | 27 |
| Industry | Computer Software: Prepackaged Software | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 25.2M | 28.3M |
| IPO Year | 2018 | 2020 |
| Metric | HKIT | PASG |
|---|---|---|
| Price | $1.07 | $8.58 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $23.50 |
| AVG Volume (30 Days) | ★ 67.4K | 28.8K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.53 | $0.28 |
| 52 Week High | $4.21 | $20.00 |
| Indicator | HKIT | PASG |
|---|---|---|
| Relative Strength Index (RSI) | 28.57 | 43.38 |
| Support Level | N/A | $8.10 |
| Resistance Level | $1.44 | $8.85 |
| Average True Range (ATR) | 0.16 | 0.73 |
| MACD | -0.10 | 0.11 |
| Stochastic Oscillator | 35.27 | 43.43 |
Hitek Global Inc is a provider of information technology consulting and solutions services. The company has two lines of businesses such as services to small and medium businesses, which consist of Anti-Counterfeiting Tax Control System tax devices, including Golden Tax Disk and printers, ACTCS services, and IT services; and services to large businesses, which include hardware sales and software sales. It generates revenues from hardware sales, software sales, IT services, and tax devices and services.
Passage Bio Inc is a genetic medicines company. The company is focused on developing transformative therapies for rare, monogenic CNS disorders. It has pipeline products such as GM1 Gangliosidosis, Frontotemporal dementia, and Krabbe Disease. The Company operates in a single reportable segment, developing and advancing genetic medicines designed to target critical underlying pathology of neurodegenerative diseases.